At the request of Xspray Pharma AB (publ), Xspray Pharma AB (publ) equity
rights will be traded on Nasdaq Stockholm as from 20 July 2023.
Security name: XSPRAY TO5
----------------------------
Short name: XSPRAY TO5
----------------------------
ISIN code: SE0020353548
----------------------------
Orderbook ID: 298552
----------------------------
Terms: One (1) equity right gives the right to subscribe for one (1) new
share in Xspray Pharma AB (publ). The exercise price when exercising
the warrant has been set to SEK 40.00 per share.
--------------------------------------------------------------------------------
Subscrip November 16, 2023 - November 30, 2023
tion
period:
--------------------------------------------------------------------------------
Last November 28, 2023
trading
day:
--------------------------------------------------------------------------------
For further information about this exchange notice, please contact
iss@nasdaq.com or + 46 8 405 60 00
Nasdaq Stockholm AB
At the request of Xspray Pharma AB (publ), Xspray Pharma AB (publ) equity
rights will be traded on Nasdaq Stockholm as from 20 July 2023.
Security name: XSPRAY TO6
----------------------------
Short name: XSPRAY TO6
----------------------------
ISIN code: SE0020353555
----------------------------
Orderbook ID: 298553
----------------------------
Terms: One (1) equity right gives the right to subscribe for one (1) new
share in Xspray Pharma AB (publ). The exercise price when exercising
the warrant has been set to SEK 40.00 per share.
--------------------------------------------------------------------------------
Subscrip April 18, 2024 - May 2, 2024
tion
period:
--------------------------------------------------------------------------------
Last April 29, 2024
trading
day:
--------------------------------------------------------------------------------
For further information about this exchange notice, please contact
iss@nasdaq.com or + 46 8 405 60 00Nasdaq Stockholm AB: New equity right for trading, Xspray Pharma AB (92/23)
© 2023 GlobeNewswire
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 14.02. | XSpray Pharma AB: Interim Report Fourth Quarter 2023 | October-December 2023, GroupNet sales amounted to SEK 0 thousand (0)Loss before tax amounted to SEK -54,513 thousand (-55,220)Earnings per share before dilution amounted to SEK -1.85 (-2.48)Cash flow... ► Artikel lesen | |
| 12.02. | After rejection, FDA re-accepts Xspray's application for would-be rival to BMS' Sprycel | ||
| 12.02. | FDA Accepts Xspray Pharma's NDA-resubmission for Dasynoc - PDUFA Date set to 31 July 2024 | Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY): The U.S. Food and Drug Administration (FDA) has accepted the resubmission of Xspray Pharma's New Drug Application (NDA) for Dasynoc, following... ► Artikel lesen | |
| 21.11.23 | Xspray Pharma AB: Xspray Pharma's XS003 Achieves Superior Bioavailability Milestone, Matching TASIGNA at Reduced Dosage | XS003, an amorphous non-crystalline nilotinib, designed to overcome therapeutic limitations of the currently available crystalline formulation of nilotinib (TASIGNA®), is the second protein kinase... ► Artikel lesen | |
| 08.11.23 | Xspray Pharma AB: DASYNOC Uptake into the Blood Remains Consistent When Taken with Omeprazole, Whereas SPRYCEL Uptake is Significantly More Impaired than Previously Understood | DASYNOC (Xspray's low dose, amorphous, non-crystalline, dasatinib) avoids interactions with proton pump inhibitors (PPIs), making it potentially the first and only dasatinib to provide patients... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen.
Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen,
bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen
Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu
verstehen sein kann.
